...Maximilian Goebel; Russell K. Brynes; David C. Yau; Randall Y. Chan; Sepehr Hamidi; Amy Alspach; Cynthia H. Ho; Maria E. Vergara-Lluri Development of post-chemotherapy histiocyte-rich pseudotumor (PHP) is an underrecognized event following therapy in lymphoma patients and may mimic residual tumor...

...Zhiguang Lin; Bobin Chen; Ting Wu; Xiaoping Xu Background/Aims: Diffuse large B cell lymphoma (DLBCL) is heterogeneous. We aimed to explore how tumor microenvironment promotes lymphoma cell aggressiveness and heterogeneity. Methods: We created a coculture system using human DLBCL cells and mouse...

... of an underlying lymphoma. Methods: FUO patients ( n = 83) who had splenomegaly and underwent splenectomy were enrolled into this retrospective single-center study. Clinical presentations were documented and risk factors suggestive of an underlying lymphoma were tested. Results: Seventy-four patients (89.2%) had...

... lymphoma with central nervous system (CNS) involvement is very poor and there is no established standard therapy. We retrospectively analyzed 18 patients (4 untreated and 14 relapsed) with systemic lymphoma with CNS involvement who received methotrexate and cytarabine-based multiagent chemotherapy...

... radiotherapy for patients with diffuse large B cell lymphoma, stages I-IV. The authors queried MEDLINE, EMBASE and the Cochrane Library databases. In addition, they also searched abstracts from ASCO, ASTRO, ASH, ECCO and ESMO from 2000 to 2013 and had a relatively stringent and appropriately defined selection...

... to in the content or advertisements. 2014 Chronic lymphoid leukemia Lymphoma Multiple myeloma PD-1 PD-L1 PD-L2 T-cell activation requires the presentation of an antigen to the T-cell receptor (TCR), via an antigen-presenting cell (APC) in the presence of a major histocompatibility complex (MHC...

...Jon E. Arnason; Katarina Luptakova; Jacalyn Rosenblatt; Dimitrios Tzachanis; David Avigan; Jeffrey I. Zwicker; James Levine; Michelle Kim; J. Anthony Parker; Barbara Grant; Robin M. Joyce Background: Not all patients with diffuse large B-cell lymphoma (DLBCL) are candidates for aggressive regimens...

... and the long-term survival [ 14 ]. A small clinical randomized study in patients with non-Hodgkin's lymphoma showed that Se supplementation during chemotherapy increases the percentage of cases with a reduction of lymphadenopathy, and decreases splenic size and bone marrow infiltration [ 15 ]. Further...

... or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Lymphoma Paraneoplastic pemphigus (PNP) was first described...

...Young Saing Kim; Jun Ho Ji; Young Hyeh Ko; Seok Jin Kim; Won Seog Kim Background: T cell/histiocyte-rich large B cell lymphoma (THRLBCL) is a rare morphological variant of diffuse large B cell lymphoma (DLBCL), accounting for 1-3% of all DLBCLs. However, its impact on treatment outcome...

...(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Lymphoma B-cell lymphoma The main distinctive property of intravascular large B cell lymphoma (IVLBCL...

... lymphomas. Under specific circumstances, it can be administered locally, as an alternative to systemic administration. We administered rituximab intrapericardially in an attempt to control pericardial effusion. We report the case of an 85-year-old woman, diagnosed with marginal zone lymphoma, who developed...

...Ilhan Lim; Joon Yeun Park; Hye Jin Kang; Jae Pil Hwang; Seung Sook Lee; Kyeong Min Kim; Tae Hyun Choi; Sung Hyun Yang; Byung Il Kim; Chang Woon Choi; Sang Moo Lim Aims: It was the aim of this paper to identify prognostic factors in patients with relapsed or refractory B-cell non-Hodgkin's lymphomas...

... from any ideas, methods, instructions or products referred to in the content or advertisements. Plasmacytoma Concurrent neoplasms Haematopathology Lymphoma Myeloproliferative neoplasm Patients with chronic-stage haematological malignancies have a higher risk of developing a second...

... on response rate (RR), overall survival (OS) and progression-free survival (PFS) in 111 patients with de novo diffuse large B cell lymphoma (DLBCL). Fifty-three patients were treated with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) and 58 patients were treated with R-CHOP (rituximab...

... lymphoma; © 2010 S. Karger AG, Basel 2010 Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording...

.... Although studies have been conducted to evaluate the effectiveness of pegfilgrastim to prevent FN in lymphoma patients receiving myelosuppressive chemotherapy, limited data is available to identify patients who are at risk of developing FN despite primary prophylaxis with pegfilgrastim (breakthrough FN...

... to solid tumors and myeloma, PTHrP-induced HHM is very rare in low-grad lymphoma including chronic lymphocytic leukemia. Therapeutical approaches consist of cytoreductive treatment and calcium-lowering therapy with bisphosphonates. 9 11 2009 29 04 2010 9 7 2010 © 2010 S. Karger AG...

... Autoimmunity Lymphoma T cell large granular lymphocytic (LGL) leukemia is a rare condition representing 2–3% of cases of mature lymphoid leukemias [ 1 ]. As in other T cell neoplasms, the association between T cell LGL and autoimmune manifestations is well-known. Such an association has been...

...Soley Bayraktar; Wilfredo Bassini; Mark Goodman We report a case of primary large B cell-type pituitary lymphoma in a 47-year-old immunocompetent female who presented with headache and cranial nerve palsy. She was treated with the DeAngelis chemotherapy protocol and achieved a complete remission...